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Abstract. The sympathetic nervous system is known to 
regulate osteoclast development. However, the involvement of 
α2-adrenergic receptors (α2-ARs) in osteoclastogenesis is not 
well understood. In the present study, their potential role in 
osteoclastogenesis was investigated. Guanabenz, clonidine and 
xylazine were used as agonists of α2-ARs, while yohimbine 
and idazoxan were employed as antagonists. Using RAW264.7 
pre-osteoclast and primary bone marrow cells, the mRNA 
expression of the osteoclast-related genes nuclear factor of 
activated T-cells, cytoplasmic 1 (NFATc1), tartrate-resistant 
acid phosphatase (TRAP) and cathepsin K was evaluated 
following induction with receptor activator of nuclear factor 
κB ligand (RANKL). TRAP staining was also conducted to 
assess effects on osteoclastogenesis in mouse bone marrow 
cells in vitro. Administration of 5-20 µM guanabenz (P<0.01, 
for RANKL-only treatment), 20 µM clonidine (P<0.05, 
for RANKL-only treatment) and 20 µM xylazine (P<0.05, 
for RANKL-only treatment) attenuated RANKL-induced 
upregulation of NFATc1, TRAP and cathepsin K mRNA. 
Furthermore, the reductions in these mRNAs by 10 µM 
guanabenz and 20 µM clonidine in the presence of RANKL 
were attenuated by 20 µM yohimbine or idazoxan (P<0.05). 
The administration of 5-20 µM guanabenz (P<0.01, for 
RANKL-only treatment) and 10-20 µM clonidine (P<0.05, 
for RANKL-only treatment) also decreased the number of 
TRAP-positive multi-nucleated osteoclasts. Collectively, the 
present study demonstrates that α2-ARs may be involved in 
the regulation of osteoclastogenesis.
Introduction
Numerous studies have reported that the central and periph-
eral sympathetic nervous systems serve important roles in 
bone remodeling and bone fracture healing (1-4). Particularly, 
bone-forming osteoblasts and bone-resorbing osteoclasts are 
established to express α- and β-adrenergic receptors (α- and 
β-ARs) (5-7). In osteoblastogenesis, it has been documented 
that α1-ARs promote cell proliferation through the suppression 
of potassium channels (8). Additionally, α1B-AR signaling 
may stimulate bone formation through the promotion of 
proliferation via upregulation of CCAAT/enhancer-binding 
protein δ in osteoblasts (9). Furthermore, it has been reported 
that leptin binding to hypothalamic receptors contributed to 
the regulation of bone homeostasis via β2-ARs (1), and that 
these β2-ARs inhibited cyclic-adenosine monophosphate 
(c-AMP)-responsive element-binding protein phosphorylation, 
leading to a decrease in osteoblast proliferation (10). α1-AR 
agonist but not β2-AR agonist may also induce fracture callus 
contraction via promotion of osteogenesis (11).
In osteoclastogenesis, it has been documented that an 
agonist to β-AR (isoprenaline) could promote bone-resorbing 
activity in human osteoclast-like cells (6). Furthermore, 
β2-ARs have been reported to stimulate osteoclastogenesis 
via reactive oxygen species generation (12). A key feature of 
ARs in bone remodeling is their ability to mediate interactions 
of osteoblasts with osteoclasts, since activation of α1- and 
β-ARs induces expression of receptor activator of nuclear 
factor κB (NF-κB) ligand (RANKL) in osteoblasts, resulting 
in RANKL-driven promotion of osteoclastogenesis (13-15). 
To the best of our knowledge, however, little is known of the 
role of agonists to α-ARs in the development of osteoclast 
precursors.
α2-ARs, the prime focus in the present study, belong to the 
G-protein-coupled receptor (GPCR) family. There are three 
α2-AR subtypes (α2A, α2B and α2C), which are established 
to regulate various physiological functions via suppression of 
adenylyl cyclase and reduction of c-AMP (16-21). For instance, 
α2-ARs on presynaptic membranes may inhibit norepineph-
rine secretion from sympathetic nerves (16). It has also been 
reported that α2A-AR serves a principal role in the hypotensive 
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response (17), and that it is a primary mediator of sedative, 
analgesic and anesthetic-sparing responses (18). Furthermore, 
α2A-AR on pancreatic β-cells has been documented to inhibit 
insulin secretion (19). Although α2-ARs have been established 
to serve various roles in homeostasis, little is understood of 
their direct involvement in osteoclastogenesis.
In the current study, RAW264.7 pre-osteoclast cells and 
primary bone marrow cells were used to evaluate the role of 
α2-ARs in osteoclastogenesis. In the presence and absence 
of α2-AR agonists (guanabenz, clonidine and xylazine) 
and α2-AR antagonists (yohimbine and idazoxan), these 
cells were cultured in an osteoclast differentiation medium. 
Real-time quantitative polymerase chain reaction (qPCR) and 
tartrate-resistant acid phosphatase (TRAP) staining, as well as 
western blot analysis, were then conducted to determine the 
effects of these agonists and antagonists in osteoclastogenesis.
Materials and methods
Animals. To harvest bone marrow cells, C57BL/6J mice were 
purchased from Chubu Kagaku Shizai Co., Ltd. (Nagoya, 
Japan). A total of 35 female mice (8-10 weeks old) were used 
in the current study. The mice were housed under a 12-h 
light/dark cycle, and water and food were provided ad libitum. 
The protocols for animal experiments were approved by 
the Aichi-Gakuin University Animal Research Committee 
(Nagoya, Japan).
Cell culture. After the female mice were scarified by cervical 
dislocation, mouse bone marrow cells were isolated from long 
bones (femur and tibia). For isolation of the bone marrow cells, 
the distal and proximal ends of the long bone were removed. 
Using a needle (25G), the bone marrow cavity was flushed out 
with phosphate‑buffered saline. The buffer was then filtered 
with a cell strainer (100 µm; BD Falcon™; BD Biosciences, 
Durham, NC, USA) and the filtered solution consisting of 
bone marrow derived cells was used (22). The mouse bone 
marrow cells as well as murine RAW264.7 pre-osteoclast cells 
obtained from American Type Culture Collection (Manassas, 
VA, USA) were cultured in α-Minimum Essential Media 
containing 10% fetal bovine serum and antibiotics (100 U/ml 
penicillin, 100 µg/ml streptomycin; Wako Pure Chemical 
Industries, Ltd., Osaka, Japan). The cells were maintained at 
37˚C with 5% CO2 in a humidified incubator.
In vitro osteoclast formation and TRAP staining. Mouse 
bone marrow cells were plated at densities of 1.2x105 and 
1.0x106 cells into 12-well and 60-mm dishes, respectively, 
and cultured with 10 ng/ml macrophage colony-stimulating 
factor (M‑CSF; PeproTech, Inc., Rocky Hill, NJ, USA) at 37˚C 
for 3 days. The surface-attached cells were used as osteoclast 
precursors (22). These cells were cultured with 10 ng/ml 
M-CSF and 50 ng/ml RANKL (PeproTech, Inc.). A total of 
5-20 µM guanabenz (R&D Systems, Inc., Minneapolis, MN, 
USA) or 10-20 µM xylazine (Sigma-Aldrich; Merck KGaA, 
Darmstadt, Germany) was applied at the same time point as 
RANKL; 10-20 µM clonidine (Sigma-Aldrich; Merck KGaA) 
was administered with RANKL or 1 day after RANKL 
administration. After a 60‑h treatment with RANKL at 37˚C, 
cells were fixed in 10% formalin neutral buffer solution at 
room temperature and stained with TRAP for 1 h at 37˚C. The 
number of TRAP-positive cells containing three or more nuclei 
was determined. All positive cells in each well were counted 
using a light microscope (magnification, x100; Zeiss AG, 
Oberkochen, Germany).
RAW264.7 cells were plated at 1.0x105 cells into 60-mm 
dishes and cultured with 25 ng/ml RANKL in the presence 
or absence of 5-20 µM guanabenz, 10-20 µM clonidine or 
10-20 µM xylazine with or without 10-20 µM yohimbine or 
10‑20 µM idazoxan (Sigma‑Aldrich; Merck KGaA) at 37˚C for 
2-4 days for qPCR analysis.
Reverse transcription‑qPCR. Mouse bone marrow cells 
and RAW264.7 cells were treated with RANKL and α2 
agonists/antagonists at 37˚C for 2‑4 days prior to qPCR 
analysis. Total RNA was extracted using an RNeasy Plus Mini 
kit (Qiagen Sciences, Inc., Gaithersburg, MD, USA). Reverse 
transcription was conducted with a High-Capacity cDNA 
Reverse Transcription kit (Applied Biosystems; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA), and real‑time qPCR was 
performed using a Takara Thermal Cycler Dice Real Time 
System III (Takara Bio, Inc., Otsu, Japan) with Thunderbird 
SYBR qPCR mix (Toyobo Life Science, Osaka, Japan). The 
PCR cycling conditions were 95˚C for 10 min (pre‑denatur-
ation), 40 cycles at 95˚C for 15 sec (denaturation) and 60˚C 
for 1 min (extension). The mRNA levels of α2A-, α2B-, and 
α2C-ARs, nuclear factor of activated T-cells, cytoplasmic 1 
(NFATc1), TRAP and cathepsin K were evaluated with the 
PCR primers listed in Table I. The expression of GAPDH was 
used as the internal control. The PCR results were interpreted 
using the 2-ΔΔCq method (23).
Western blot analysis. RAW264.7 cells were lysed in 1X 
radioimmunoprecipitation assay buffer containing protease 
inhibitors (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) 
and phosphatase inhibitors (Merck KGaA). Isolated proteins 
were quantified using a Pierce bicinchoninic acid protein assay 
kit (Thermo Fisher Scientific, Inc.). A total of 10 µg protein 
per lane was fractioned using 10% SDS gels and electro-trans-
ferred to Immobilon-P membranes (EMD Millipore, Billerica, 
MA, USA). The membranes were blocked with 1% nonfat 
dry milk at 4˚C for overnight (Bio‑Rad Laboratories, Inc., 
Hercules, CA, USA). The membranes were then incubated for 
1 h at room temperature with primary antibodies followed by 
a 45-min incubation at room temperature with goat anti-rabbit 
(2,000-fold dilution) or anti-mouse (2,000-fold dilution) immu-
noglobulin G conjugated with horseradish peroxidase (cat. 
nos. 7074 and 7076, respectively; Cell Signaling Technology, 
Inc., Danvers, MA, USA). The primary antibodies used were 
against eukaryotic translation initiation factor 2α (eIF2α; 
1,000-fold dilution; cat. no. 9722; Cell Signaling Technology, 
Inc.), phosphorylated (p)-eIF2α (1,000-fold dilution; cat. 
no. PA1‑26686; Thermo Fisher Scientific, Inc.) and β-actin 
(10,000-fold dilution; cat. no. A5441; Sigma-Aldrich; Merck 
KGaA). Protein levels were assayed using a SuperSignal 
West Femto Maximum Sensitivity Substrate (Thermo Fisher 
Scientific, Inc.). To determine band intensities, images were 
scanned with a luminescent image analyzer (LAS-3000; 
Fujifilm, Tokyo, Japan) and quantified using Image J v1.48 
(National Institutes of Health, Bethesda, MD, USA).
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Statistical analysis. Statistical analyses were performed using 
Microsoft Excel for Mac 2011 (version 14.6.9; Microsoft 
Corporation, Redmond, WA, USA). Data were expressed as 
the mean ± standard deviation of three to five independent 
experiments. Statistical significance was evaluated using 
Student's t-test at P<0.05.
Results
mRNA expression of α2‑ARs. The mRNA levels of α2A-, 
α2B- and α2C-ARs were determined. All three of the α2-ARs 
were detectable (Fig. 1). However, the responses to RANKL 
differed between RAW264.7 and primary bone marrow 
cells. RANKL administration on days 0, 2 and 4 did not 
significantly alter the mRNA levels of α2-ARs in RAW264.7 
cells (Fig. 1A); while it significantly altered their mRNA levels 
in primary bone marrow cells when detected after 2 days. 
Specifically, the mRNA expression of α2A- and α2C-ARs 
was significantly downregulated by RANKL administration 
(P<0.01 and P<0.05, respectively), while that of α2B-AR was 
upregulated (P<0.01; Fig. 1B).
α2‑AR agonist‑driven reduction in the expression of osteoclast 
genes. On day 2 following the administration of RANKL, the 
mRNA levels of NFATc1, TRAP and cathepsin K were signifi-
cantly reduced by 5-20 µM guanabenz in RAW264.7 and 
primary bone marrow cells (P<0.01; Fig. 2). Administration 
of 20 µM clonidine consistently suppressed RANKL-induced 
Figure 1. mRNA expression of α2-ARs. (A) mRNA levels of α2A-, α2B- and α2C-ARs on days 0, 2 and 4 after administration of RANKL in RAW264.7 cells. 
(B) mRNA levels of α2A-, α2B- and α2C-ARs on days 0 and 2 after administration of RANKL in primary bone marrow cells. *P<0.05 and **P<0.01 vs. day 0. 
α2-AR, α2-adrenergic receptors; RANKL, receptor activator of nuclear factor κB ligand.
Table I. Real-time polymerase chain reaction primers used in the present study.
 Primer sequence (5'-3')
 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Target Forward  Reverse 
α2A-AR GGTGTGTTGGTTTCCGTTCT CGGAAGTCGTGGTTGAAGAT
α2B-AR TCGGAGAGGCTAATGGACAC TCTTCAGCTCCCTTCTCTGC
α2C-AR (ref. 7) CATGGGCGTGTTCGTACTGT CAGGCCTCACGGCAGATG
Cathepsin K CAGCTTCCCCAAGATGTGAT AGCACCAACGAGAGGAGAAA
NFATc1 GGTGCTGTCTGGCCATAACT GCGGAAAGGTGGTATCTCAA
TRAP TCCTGGCTCAAAAAGCAGTT ACATAGCCCACACCGTTCTC
GAPDH TGCACCACCAACTGCTTAG GGATGCAGGGATGATGTTC
α2-AR, α2-adrenergic receptors; NFATc1, nuclear factor of activated T-cells, cytoplasmic 1; TRAP, tartrate-resistant acid phosphatase.
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upregulation of NFATc1, TRAP and cathepsin K on days 2 
and 4 in RAW264.7 cells (P<0.05; Fig. 3A and B). In primary 
bone marrow cells, administration of 10-20 µM clonidine 
suppressed the mRNA levels of the osteoclast genes when 
clonidine was applied alongside RANKL (P<0.01; Fig. 3C). 
However, when clonidine was administered 1 day after the 
administration of RANKL, it did not alter the mRNA levels 
of NFATc1, TRAP or cathepsin K (Fig. 3D). The mRNA levels 
of these osteoclast genes were also consistently downregulated 
by 20 µM xylazine in RAW264.7 and primary bone marrow 
cells on day 2 after administration of RANKL (P<0.05; Fig. 4).
Suppression of α2‑AR agonist‑driven reduction of osteoclast 
gene expression by yohimbine or idazoxan. The reduction 
in the mRNA levels of NFATc1, TRAP and cathepsin K 
in response to guanabenz and clonidine was consistently 
suppressed by 20 µM yohimbine (P<0.05; Fig. 5A and B) or 
20 µM idazoxan (P<0.05; Fig. 6). This result indicates that 
α2-AR antagonists inhibit the action of α2-AR agonists, and 
also supports the notion that α2-ARs may be involved in regu-
lation of osteoclast gene expression. Of note, administration of 
yohimbine alone upregulated the expression of the osteoclast 
genes at concentrations of 10 (P<0.05) and 20 (P<0.01) µM 
(Fig. 5C).
Inhibitory effects of α2‑AR agonist on osteoclastogenesis. In 
RANKL-induced primary bone marrow cells, guanabenz and 
clonidine suppressed osteoclastogenesis in a dose-dependent 
manner (Fig. 7). The number of TRAP-positive multi-nucle-
ated osteoclasts was significantly reduced by 5, 10 and 20 µM 
guanabenz (P<0.01) and 10 and 20 µM clonidine (P<0.05 and 
P<0.01, respectively).
Increase in eIF2α phosphorylation by guanabenz. Guanabenz 
is established to suppress osteoclastogenesis by inhibiting 
dephosphorylation of eIF2α (24-26). To determine whether 
clonidine and xylazine also inhibit dephosphorylation of 
eIF2α, the level of p-eIF2α was assessed in RAW264.7 cells. 
Western blot analysis demonstrated that administration of 
20 µM guanabenz increased the phosphorylation of eIF2α 
(P<0.05), while treatment with 20 µM clonidine or xylazine 
did not significantly affect the phosphorylation level (Fig. 8).
Discussion
The current study demonstrated that three chemical agents, 
guanabenz, clonidine and xylazine, which serve as α2-AR 
agonists, suppressed the mRNA expression of three osteo-
clast genes (NFATc1, TRAP and cathepsin K) in RAW264.7 
and primary bone marrow cells, and reduced the number of 
TRAP-positive multi-nucleated osteoclasts in mouse bone 
marrow cells. Consistent with the observed involvement of 
α2-ARs in response to guanabenz and clonidine, adminis-
tration of yohimbine and idazoxan, as α2-AR antagonists, 
suppressed the α2-AR agonist-induced reduction in the mRNA 
levels of the target genes. Compared with clonidine and xyla-
zine, the results also indicated that the greater inhibitory effect 
of guanabenz in osteoclastogenesis may be associated with a 
guanabenz-driven elevation in p-eIF2α. Furthermore, the find-
ings suggest that the responses to agents including clonidine 
Figure 2. Suppression of RANKL-induced osteoclast gene expression in response to guanabenz in RAW264.7 and primary bone marrow cells. 
(A) Guanabenz-induced inhibition of NFATc1, TRAP and cathepsin K on day 2 after administration of RANKL in RAW264.7 cells. (B) Guanabenz-induced 
inhibition of NFATc1, TRAP and cathepsin K on day 2 after administration of RANKL in primary bone marrow cells. **P<0.01 vs. RANKL-only treatment. 
NFATc1, nuclear factor of activated T-cells, cytoplasmic 1; TRAP, tartrate-resistant acid phosphatase; RANKL, receptor activator of nuclear factor κB ligand.
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may differ depending on the administration window during 
osteoclastogenesis.
Since yohimbine and idazoxan are established to serve as 
α2-AR antagonists (27), it was determined whether yohimbine 
and idazoxan could suppress the effect of α2-AR agonists 
including guanabenz and clonidine. The results demonstrated 
that administration of yohimbine or idazoxan suppressed 
α2-AR agonist-driven reduction in the expression of osteo-
clast genes. This indicates that the selected antagonists may 
block binding of agonists to α2-ARs. Notably, administra-
tion of yohimbine alone increased mRNA expression of the 
osteoclast genes. It has been reported that certain ionotropic 
receptors, including the γ-aminobutyric acid A receptors, as 
well as GPCRs, including adrenergic, histamine and adenosine 
receptors, are constitutively activated even in the absence of 
agonists, and this constitutive activity may be inhibited by 
so-called inverse agonists (28-32). For instance, adenosine A1 
receptor is constitutively activated in osteoclast precursors and 
rolofylline, a receptor antagonist, has been reported to inhibit 
osteoclast differentiation as an inverse agonist (32). Yohimbine 
may also serve as an inverse agonist of α2-ARs, resulting in 
increased expression of osteoclast genes.
Figure 3. Suppression of RANKL-induced osteoclast genes in response to clonidine in RAW264.7 and primary bone marrow cells. (A) Clonidine-induced 
inhibition of NFATc1, TRAP and cathepsin K on day 2 after administration of RANKL in RAW264.7 cells. (B) Clonidine-induced inhibition of NFATc1, 
TRAP and cathepsin K on day 4 after administration of RANKL in RAW264.7 cells. (C) Clonidine-induced inhibition of NFATc1, TRAP and cathepsin K 
on day 2 after administration of RANKL in primary bone marrow cells. (D) Undetectable alteration in the mRNA levels of NFATc1, TRAP and cathepsin K 
on day 2 by clonidine in primary bone marrow cells. Clonidine was applied at the same time point with RANKL in the experiment for (A-C) but was applied 
1 day after administration of RANKL in the experiment for (D). *P<0.05 and **P<0.01 vs. RANKL-only treatment. NFATc1, nuclear factor of activated T-cells, 
cytoplasmic 1; TRAP, tartrate-resistant acid phosphatase; RANKL, receptor activator of nuclear factor κB ligand.
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Although guanabenz, clonidine and xylazine are α2-AR 
agonists, there are differences in specificity among these 
agents. Guanabenz is known to inhibit dephosphorylation of 
eIF2α and attenuate endoplasmic reticulum stress, leading to 
downregulation of osteoclast genes and attenuation of osteo-
clastogenesis (24-26). Consistent with the action of guanabenz, 
western blot analysis revealed that administration of guana-
benz to RAW264.7 cells elevated the level of p-eIF2α, while 
administration of clonidine or xylazine did not significantly 
alter the phosphorylation level. This result indicates that 
guanabenz serves as an inhibitor of eIF2α dephosphorylation, 
as well as an α2-AR agonist, and induces stronger suppres-
sion of osteoclast genes and attenuation of osteoclastogenesis 
compared with clonidine and xylazine.
The action of clonidine and guanabenz via α2-ARs is 
possibly mediated by c-AMP, since RANKL has been reported 
to increase the level of c-AMP in osteoclast precursors (33). 
Elevation of c-AMP may activate exchange protein directly 
activated by c-AMP (34,35), which has been documented to 
promote osteoclast differentiation via nuclear translocation 
of NF-κB (33). Furthermore, activation of an adenylyl cyclase 
followed by elevation of c-AMP upregulated c-Fos, which 
is established to promote osteoclast development (36,37). 
Since α2-ARs are known to suppress adenylyl cyclase and 
reduce c-AMP (21), and clonidine and guanabenz have been 
reported to reduce c-Fos expression (25,38), it is possible that 
the α2 agonists in the current study reduce RANKL-induced 
c-AMP, resulting in the suppression of osteoclastogenesis.
While clonidine served as an inhibitor of osteoclasto-
genesis in the current study, its effect during the course of 
osteoclastogenesis is not completely understood. A previous 
report identified that clonidine increased the number of 
TRAP-positive osteoclasts in mouse bone marrow cells, 
and that its administration did not alter the number of 
TRAP-positive osteoclasts in α2A and α2C double knockout 
mice (7). It has also been reported that the number of 
TRAP-positive osteoclasts was not affected by clonidine in 
cluster of differentiation 14+ osteoclast precursors (39). A 
major difference among these studies appears to be the timing 
of clonidine administration. In the current study, clonidine 
was applied on day 0 together with RANKL or 1 day after 
administration of RANKL, while it was administered on 
days 2 and 11 in the previous reports (7,39). The present study 
revealed that when clonidine was applied alongside RANKL 
in primary bone marrow cells, it suppressed the mRNA levels 
of NFATc1, TRAP and cathepsin K; however, when clonidine 
was administered 1 day after the administration of RANKL, 
it did not alter mRNA levels. Therefore, as the mRNA levels 
of α2A- and α2C-ARs in primary bone marrow cells were 
downregulated on day 2, it is possible that the efficacy of 
clonidine as an inhibitor may depend on the timing of its 
administration as well as the expression profiles of α2A and 
α2C receptors.
While it was demonstrated in the current study that α2-ARs 
on osteoclast precursors suppressed osteoclastogenesis, 
pre-clinical studies in laboratory animals are necessary prior 
to clinical studies and application in patients. As the current 
study was an in vitro analysis, animal studies using conditional 
knockout mice or other appropriate models are recommended 
to verify the present findings. Nonetheless, the results indicated 
that α2-ARs may be involved in the regulation of osteoclasto-
genesis in RAW264.7 and primary bone marrow cells in vitro.
Figure 4. Suppression of RANKL-driven osteoclast genes in response to xylazine in RAW264.7 and primary bone marrow cells. (A) Xylazine-induced inhibi-
tion of NFATc1, TRAP and cathepsin K on day 2 after administration of RANKL in RAW264.7 cells. (B) Xylazine-induced inhibition of NFATc1, TRAP and 
cathepsin K on day 2 after administration of RANKL in primary bone marrow cells. *P<0.05 and **P<0.01 vs. RANKL-only treatment. NFATc1, nuclear factor 
of activated T-cells, cytoplasmic 1; TRAP, tartrate-resistant acid phosphatase; RANKL, receptor activator of nuclear factor κB ligand.
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Figure 5. Reduction in guanabenz and clonidine-induced suppression of osteoclast genes by yohimbine in RAW264.7 cells. (A) Reduction in guanabenz-induced 
suppression of NFATc1, TRAP and cathepsin K by yohimbine on day 2 after administration of RANKL in RAW264.7 cells. Note that the asterisks denote 
the comparison of RANKL with guanabenz. (B) Reduction in clonidine-induced suppression of NFATc1, TRAP and cathepsin K by yohimbine on day 2 
after administration of RANKL in RAW264.7 cells. Note that the asterisks are to compare RANKL with clonidine. (C) Upregulation of NFATc1, TRAP 
and cathepsin K by yohimbine on day 2 after administration of RANKL in RAW264.7 cells. *P<0.05 and **P<0.01 vs. RANKL with guanabenz treatment; 
#P<0.05 and ##P<0.01 vs. RANKL with clonidine treatment; $P<0.05 and $$P<0.01 vs. RANKL-only treatment. NFATc1, nuclear factor of activated T-cells, 
cytoplasmic 1; TRAP, tartrate-resistant acid phosphatase; RANKL, receptor activator of nuclear factor κB ligand.
Figure 6. Reduction in guanabenz-induced suppression of osteoclast genes by idazoxan in RAW264.7 cells. Reduction in guanabenz-induced suppression of NFATc1, 
TRAP and cathepsin K by idazoxan on day 2 after administration of RANKL in RAW264.7 cells. *P<0.05 and **P<0.01 vs. RANKL with guanabenz treatment. 
NFATc1, nuclear factor of activated T-cells, cytoplasmic 1; TRAP, tartrate-resistant acid phosphatase; RANKL, receptor activator of nuclear factor κB ligand.
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Figure 8. Inhibition of eIF2α dephosphorylation by guanabenz. (A) Elevated level of p-eIF2α in RAW264.7 cells following treatment with 20 µM guanabenz 
for 24 h. Notably, 20 µM clonidine and xylazine did not significantly alter phosphorylation level. (B) Relative intensities of (p‑eIF2α)/(total eIF2α). *P<0.05 
vs. RANKL-only treatment. eIF2α, eukaryotic translation initiation factor 2α; RANKL, receptor activator of nuclear factor κB ligand; p-, phosphorylated.
Figure 7. Inhibitory effects of α2-adrenergic receptor agonist on the development of osteoclasts in the presence of 50 ng/ml RANKL. (A) Dose-dependent sup-
pression of TRAP-positive multi-nucleated osteoclasts by guanabenz in bone marrow cells. (B) Dose-dependent suppression of TRAP-positive multi-nucleated 
osteoclasts by clonidine in primary bone marrow cells. *P<0.05 and **P<0.01 vs. RANKL-only treatment. RANKL, receptor activator of nuclear factor κB 
ligand; CN control.
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